Loading…
AstraZeneca PLC is projected to rise to $208.78 by 2027, a +12% move from its current price of $185.65. AZN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $183.63 | $185.63 | $187.66 | -0.01% |
| May 30 | $182.80 | $185.62 | $188.48 | -0.02% |
| May 31 | $182.15 | $185.60 | $189.12 | -0.03% |
| Jun 1 | $181.61 | $185.59 | $189.65 | -0.03% |
| Jun 2 | $181.13 | $185.57 | $190.12 | -0.04% |
| Jun 3 | $180.70 | $185.55 | $190.54 | -0.05% |
| Jun 4 | $180.30 | $185.54 | $190.93 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $180.30 | $185.54 | $190.93 | -0.06% |
| Week 2 | $178.06 | $185.42 | $193.09 | -0.12% |
| Week 3 | $176.34 | $185.31 | $194.74 | -0.18% |
| Week 4 | $174.88 | $185.20 | $196.12 | -0.24% |
| Week 5 | $173.60 | $185.09 | $197.33 | -0.30% |
| Week 6 | $172.43 | $184.97 | $198.42 | -0.36% |
| Week 7 | $171.36 | $184.86 | $199.42 | -0.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AstraZeneca PLC is a biopharmaceutical company focused on the discovery, development, manufacture, and commercialization of prescription medicines. The portfolio includes Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.
The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC, traded under the symbol AZN, is a global biopharmaceutical company with a diversified prescription medicines portfolio and operations worldwide. The stock currently trades at $187.03 and carries a market capitalization of $290.06B, ranking 45 by size. The near-term price setup shows resistance around $204.80 with support near $181.24, as the stock has traded within a 30-day range of $173.52 to $201.59.
The broader forecast implies a rising trajectory over the coming years, with year-specific averages around the $200s to the $1,000s by 2050.
A major floor 10.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.4% away) — a key level to hold.
The nearest ceiling, 10.3% above — a clean break opens room to run.
A major ceiling 15.3% above — clearing it would confirm fresh momentum.
Key AZN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AZN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $187.42 | Sell | $186.52 | Sell |
| MA 10 | $185.99 | Sell | $186.18 | Sell |
| MA 20 | $184.93 | Buy | $186.87 | Sell |
| MA 50 | $191.05 | Sell | $189.62 | Sell |
| MA 100 | $192.42 | Sell | $188.52 | Sell |
| MA 200 | $180.62 | Buy | $180.71 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.22 | Neutral |
| Stoch RSI (14) | 61.18 | Neutral |
| CCI (20) | 26.73 | Neutral |
| Williams %R (14) | -50.18 | Info |
| MACD (12,26,9) | 0.74 | Buy |
| ROC (12) | 1.53 | Buy |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 49.82 | Neutral |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | -2.83 | Sell |
| Ultimate (7,14,28) | 57.96 | Neutral |
| Momentum (10) | 1.11 | Buy |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 188.01 | Sell |
| ADX (14) | 15.27 | Neutral |
| ATR (14) | 2.12 | Info |
The 30-day technical picture is bullish. The RSI(14) stands at 50, with the 50-day simple moving average at $191.23 and the 200-day simple moving average at $180.24, placing current price action near key moving averages. Immediate support sits at $181.24 and resistance at $204.80, with the stock trading in a 30-day range from $173.52 to $201.59.
Annualized volatility is about 20%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $179.88 | $185.65 | $242.08 | 0% | Neutral | |
| $170.56 | $208.78 | $267.50 | +12% | Neutral | |
| $185.92 | $231.74 | $304.69 | +25% | Bullish | |
| $200.68 | $253.93 | $340.80 | +37% | Bullish | |
| $242.04 | $310.33 | $423.88 | +67% | Bullish | |
| $271.51 | $352.33 | $488.74 | +90% | Bullish | |
| $278.23 | $365.09 | $513.56 | +97% | Bullish | |
| $296.72 | $393.43 | $560.51 | +112% | Bullish | |
| $310.66 | $415.98 | $599.66 | +124% | Bullish | |
| $328.05 | $443.40 | $646.24 | +139% | Bullish | |
| $461.72 | $650.79 | $993.70 | +251% | Bullish | |
| $916.22 | $1,384.79 | $2,265.89 | +646% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $179.88 | $185.65 | $216.48 | +0.00% |
| June 2026 | $155.72 | $181.66 | $216.03 | -2.15% |
| July 2026 | $156.98 | $184.18 | $221.10 | +1.39% |
| August 2026 | $158.30 | $186.57 | $225.59 | +1.30% |
| September 2026 | $156.40 | $185.02 | $225.04 | -0.83% |
| October 2026 | $157.93 | $187.46 | $229.25 | +1.32% |
| November 2026 | $163.10 | $194.18 | $238.58 | +3.58% |
| December 2026 | $164.29 | $196.15 | $242.08 | +1.01% |
Click any year to see its month-by-month AZN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AZN could reach as high as $242.08, with a base case around $185.65 and support toward $179.88 — roughly 0% from $185.65. Price action looks broadly range-bound.
Expect AZN to range from $170.56 to $267.50 through 2027. The $208.78 average target implies a +12% move from current prices. That is up +12% on the projected 2026 average. A consolidation phase looks the most probable path here.
The AZN price prediction for 2028 points to an average of $231.74 (low $185.92, high $304.69) — a potential gain of +25% on today's $185.65. Momentum favours further upside here.
In 2029, AZN is projected to trade between $200.68 and $340.80, averaging $253.93 — a potential gain of +37% from today's $185.65. That is up +10% on the projected 2028 average. Buyers look set to stay in control over this stretch.
AstraZeneca PLC's 2030 outlook centres on $310.33, within a $242.04 to $423.88 range. That is up +22% on the projected 2029 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2031, AZN could reach as high as $488.74, with a base case around $352.33 and support toward $271.51 — roughly +90% from $185.65. Buyers look set to stay in control over this stretch.
Expect AZN to range from $278.23 to $513.56 through 2032. The $365.09 average target implies a +97% move from current prices. That is up +4% on the projected 2031 average. Momentum favours further upside here.
The AZN price prediction for 2033 points to an average of $393.43 (low $296.72, high $560.51) — a potential gain of +112% on today's $185.65. Buyers look set to stay in control over this stretch.
In 2034, AZN is projected to trade between $310.66 and $599.66, averaging $415.98 — a potential gain of +124% from today's $185.65. That is up +6% on the projected 2033 average. Momentum favours further upside here.
AstraZeneca PLC's 2035 outlook centres on $443.40, within a $328.05 to $646.24 range. That is up +7% on the projected 2034 average. That marks a +139% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, AZN could reach as high as $993.70, with a base case around $650.79 and support toward $461.72 — roughly +251% from $185.65. Momentum favours further upside here.
Expect AZN to range from $916.22 to $2,265.89 through 2050. The $1,384.79 average target implies a +646% move from current prices. That is up +113% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AZN today (≈ 5.38648 AZN) could be worth
$7,459.14
+$6,459.14 (+646%) by 2050 · US Dollar
Based on the average projected AZN price of $1,384.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AZNwould be worth at today's price.
$1,000 invested in AZN on May 27, 2025 (≈ 7.046223 AZN) would be worth
$1,308.13
+$308.13 (+30.8%) today · 1.31× · US Dollar
Based on a AZN entry price of $141.92 vs. today's $185.65.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $187.46 | $990.34 | -1.0% |
| 1 month ago | $187.51 | $990.08 | -1.0% |
| 3 months ago | $203.98 | $910.14 | -9.0% |
| 6 months ago | $185.44 | $1,001.13 | +0.1% |
| 1 year ago | $141.92 | $1,308.13 | +30.8% |
| All time (5.0y) ago | $112.5 | $1,650.22 | +65.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AZN forecast.
Our base-case forecast reaches $370.00 around 2033.
Implied market cap at $370.00: $573.81B
Multi-year forecasts show a strong upside path, led by bullish sentiment from 2028 onward. The 2026 forecast is min $179.88, avg $187.03, max $243.94 with ROI 0%. By 2027, avg rises to $210.76 (ROI 12.7%), and 2028 shows avg $235.30 (ROI 25.8%).
The 2029 forecast is avg $257.15 (ROI 37.5%), and 2030 reaches avg $315.51 (ROI 68.7%). The sequence continues with 2031 avg $358.53 (ROI 91.7%), 2032 avg $369.29 (ROI 97.5%), 2033 avg $400.82 (ROI 114.3%), 2034 avg $424.55 (ROI 127%), and 2035 avg $449.03 (ROI 140.1%). Looking further out, 2040 shows avg $664.58 (ROI 255.3%) and 2050 shows avg $1,412.17 (ROI 655%).
These figures reflect bullish expectations but remain estimates, not guarantees, and are subject to market risk.
Tap a question to reveal the answer.
Avg $315.51; min $246.03; max $431.04; ROI 68.7%; Sentiment BULLISH.
Forecasts show a rising Avg price over time with 2030 avg $315.51 and 2040 avg $664.58, culminating in 2050 avg $1,412.17 and ROI of 68.7% to 655%. These are estimates and not guarantees.
The 30-day resistance level is $204.80.
Current price is $187.03 and market capitalization is $290.06B.
Low: $173.52; High: $201.59.
AstraZeneca PLC Community Discussion
0Share your AstraZeneca PLC price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.